NASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis $25.45 -1.30 (-4.86%) Closing price 04:00 PM EasternExtended Trading$25.44 -0.01 (-0.04%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vera Therapeutics Stock (NASDAQ:VERA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vera Therapeutics alerts:Sign Up Key Stats Today's Range$25.16▼$27.1550-Day Range$25.58▼$36.2652-Week Range$25.08▼$56.05Volume1.37 million shsAverage Volume1.61 million shsMarket Capitalization$1.84 billionP/E RatioN/ADividend YieldN/APrice Target$74.93Consensus RatingModerate Buy Company Overview Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs. Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases. The candidate is investigational and has not been approved for commercial use. Vera was founded by physician and biotechnology executive Marshall Fordyce, who serves as the company’s chief executive officer. Its development work and clinical trials support its efforts to advance potential treatments for patients in the United States and other regions.AI Generated. May Contain Errors. Read More Vera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreVERA MarketRank™: 3.444962942625 of 5 starsVera Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 210th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialVera Therapeutics has a consensus price target of $74.93, representing about 194.4% upside from its current price of $25.45.Amount of Analyst CoverageVera Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vera Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vera Therapeutics are expected to grow in the coming year, from ($6.00) to ($3.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted20.03% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 8.47.Change versus previous monthShort interest in Vera Therapeutics has recently decreased by 10.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.00 News SentimentVera Therapeutics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vera Therapeutics this week, compared to 5 articles on an average week.Search Interest9 people have searched for VERA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,334,220.00 in company stock.Percentage Held by Insiders15.90% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vera Therapeutics' insider trading history. Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERA Stock News HeadlinesVera Therapeutics Earnings Call Highlights TRUTAKNA MomentumNovember 16, 2026 | theglobeandmail.comJ.P. Morgan Remains a Buy on Vera Therapeutics (VERA)November 14, 2026 | theglobeandmail.comBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.November 20 at 1:00 AM | Banyan Hill Publishing (Ad)HC Wainwright Lifts Earnings Estimates for Vera TherapeuticsNovember 12, 2026 | americanbankingnews.comVera Therapeutics (VERA) Receives a Hold from WedbushNovember 8, 2026 | theglobeandmail.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 6, 2026 | globenewswire.comVera Therapeutics (VERA) Stock Looks Above Fair Value After A 148% RunNovember 6, 2026 | finance.yahoo.comVera Therapeutics (VERA) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | finance.yahoo.comSee More Headlines VERA Stock Analysis - Frequently Asked Questions How have VERA shares performed this year? Vera Therapeutics' stock was trading at $50.64 on January 1st, 2026. Since then, VERA shares have decreased by 49.7% and is now trading at $25.45. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($1.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.62) by $0.32. The business had revenue of $10.28 million for the quarter, compared to analysts' expectations of $3.42 million. Read the conference call transcript. When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $65 million in an initial public offering on Thursday, May 13th 2021. The company issued 4,350,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO. Who are Vera Therapeutics' major shareholders? Vera Therapeutics' top institutional shareholders include State Street Corp (4.58%), Pictet Asset Management Holding SA (2.55%), Integral Health Asset Management LLC (2.08%) and Goldman Sachs Group Inc. (1.97%). Insiders that own company stock include Commodore Capital Lp, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Laurence Matthew Skelton, Robert Brenner, David Lee Johnson, William D Turner and Patrick G Enright. View institutional ownership trends. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include Iovance Biotherapeutics (IOVA), Palantir Technologies (PLTR), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA) and Intel (INTC). Company Calendar Last Earnings11/05/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VERA's financial health is in the Red zone, according to TradeSmith. VERA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VERA CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees362Year Founded2016Price Target and Rating Average Price Target for Vera Therapeutics$74.93 High Price Target$125.00 Low Price Target$29.00 Potential Upside/Downside+194.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($5.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.61 million Net MarginsN/A Pretax Margin-4,041.18% Return on Equity-90.03% Return on Assets-70.54% Debt Debt-to-Equity Ratio0.23 Current Ratio7.91 Quick Ratio7.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book5.52Miscellaneous Outstanding Shares72,300,000Free Float60,803,000Market Cap$1.84 billion OptionableOptionable Beta1.07 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:VERA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.